Altheia Science is a cutting-edge biotechnology startup headquartered in Italy, founded in 2017 by renowned Italian scientists Prof. Alessandra Biffi, MD and Prof. Paolo Fiorina, MD, PhD along with AurorA-TT. The company specializes in developing innovative treatments for autoimmune diseases and cancer using pioneering therapeutic tools. Its approach involves the modulation of PD-L1 expression at the molecular and protein level, aiming to achieve tangible and durable benefits for each patient. Altheia Science secured a significant $11.00M Series A investment on 24 September 2018 from Rottapharm Biotech. With its groundbreaking approach and strong backing, Altheia Science is poised to make a substantial impact in the fields of biotechnology and healthcare.
No recent news or press coverage available for Altheia Science.